vs
ENERPAC TOOL GROUP CORP（EPAC）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是ENERPAC TOOL GROUP CORP的1.5倍（$219.9M vs $144.2M），ENERPAC TOOL GROUP CORP净利率更高（13.3% vs -1.0%，领先14.3%），Orthofix Medical Inc.同比增速更快（2.0% vs -0.7%），Orthofix Medical Inc.自由现金流更多（$16.8M vs $13.3M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 2.1%）
恩派克工具集团前身为Actuant公司，成立于1910年，总部位于美国威斯康星州梅诺莫尼福尔斯，是一家历史悠久的工业工具企业，其普通股在纽约证券交易所上市，股票代码为EPAC。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
EPAC vs OFIX — 直观对比
营收规模更大
OFIX
是对方的1.5倍
$144.2M
营收增速更快
OFIX
高出2.7%
-0.7%
净利率更高
EPAC
高出14.3%
-1.0%
自由现金流更多
OFIX
多$3.5M
$13.3M
两年增速更快
OFIX
近两年复合增速
2.1%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $144.2M | $219.9M |
| 净利润 | $19.1M | $-2.2M |
| 毛利率 | 50.7% | 71.1% |
| 营业利润率 | 19.8% | 0.2% |
| 净利率 | 13.3% | -1.0% |
| 营收同比 | -0.7% | 2.0% |
| 净利润同比 | -11.9% | 92.4% |
| 每股收益（稀释后） | $0.36 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EPACOFIX
| Q4 25 | $144.2M | $219.9M | ||
| Q3 25 | $167.5M | $205.6M | ||
| Q2 25 | $158.7M | $203.1M | ||
| Q1 25 | $145.5M | $193.6M | ||
| Q4 24 | $145.2M | $215.7M | ||
| Q3 24 | $158.7M | $196.6M | ||
| Q2 24 | $150.4M | $198.6M | ||
| Q1 24 | $138.4M | $188.6M |
净利润EPACOFIX
| Q4 25 | $19.1M | $-2.2M | ||
| Q3 25 | $28.1M | $-22.8M | ||
| Q2 25 | $22.0M | $-14.1M | ||
| Q1 25 | $20.9M | $-53.1M | ||
| Q4 24 | $21.7M | $-29.1M | ||
| Q3 24 | $24.4M | $-27.4M | ||
| Q2 24 | $25.8M | $-33.4M | ||
| Q1 24 | $17.8M | $-36.0M |
毛利率EPACOFIX
| Q4 25 | 50.7% | 71.1% | ||
| Q3 25 | 50.1% | 72.2% | ||
| Q2 25 | 50.4% | 68.7% | ||
| Q1 25 | 50.5% | 62.8% | ||
| Q4 24 | 51.4% | 69.0% | ||
| Q3 24 | 48.8% | 68.7% | ||
| Q2 24 | 51.8% | 67.8% | ||
| Q1 24 | 51.6% | 67.5% |
营业利润率EPACOFIX
| Q4 25 | 19.8% | 0.2% | ||
| Q3 25 | 23.8% | -8.3% | ||
| Q2 25 | 20.0% | -7.9% | ||
| Q1 25 | 21.2% | -25.2% | ||
| Q4 24 | 21.4% | -5.3% | ||
| Q3 24 | 18.9% | -9.6% | ||
| Q2 24 | 22.2% | -12.5% | ||
| Q1 24 | 21.3% | -15.6% |
净利率EPACOFIX
| Q4 25 | 13.3% | -1.0% | ||
| Q3 25 | 16.8% | -11.1% | ||
| Q2 25 | 13.9% | -6.9% | ||
| Q1 25 | 14.4% | -27.4% | ||
| Q4 24 | 15.0% | -13.5% | ||
| Q3 24 | 15.4% | -13.9% | ||
| Q2 24 | 17.1% | -16.8% | ||
| Q1 24 | 12.9% | -19.1% |
每股收益（稀释后）EPACOFIX
| Q4 25 | $0.36 | $-0.05 | ||
| Q3 25 | $0.51 | $-0.57 | ||
| Q2 25 | $0.41 | $-0.36 | ||
| Q1 25 | $0.38 | $-1.35 | ||
| Q4 24 | $0.40 | $-0.76 | ||
| Q3 24 | $0.44 | $-0.71 | ||
| Q2 24 | $0.47 | $-0.88 | ||
| Q1 24 | $0.33 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $139.0M | $82.0M |
| 总债务越低越好 | $188.8M | — |
| 股东权益账面价值 | $431.1M | $450.0M |
| 总资产 | $818.1M | $850.6M |
| 负债/权益比越低杠杆越低 | 0.44× | — |
8季度趋势，按日历期对齐
现金及短期投资EPACOFIX
| Q4 25 | $139.0M | $82.0M | ||
| Q3 25 | $151.6M | $62.9M | ||
| Q2 25 | $140.5M | $65.6M | ||
| Q1 25 | $119.5M | $58.0M | ||
| Q4 24 | $130.7M | $83.2M | ||
| Q3 24 | $167.1M | $30.1M | ||
| Q2 24 | $132.4M | $26.4M | ||
| Q1 24 | $153.7M | $27.0M |
总债务EPACOFIX
| Q4 25 | $188.8M | — | ||
| Q3 25 | $190.0M | $157.2M | ||
| Q2 25 | $191.3M | $157.0M | ||
| Q1 25 | $192.5M | $156.9M | ||
| Q4 24 | $193.8M | $157.0M | ||
| Q3 24 | $195.0M | $118.5M | ||
| Q2 24 | $196.3M | $118.0M | ||
| Q1 24 | $245.5M | $118.2M |
股东权益EPACOFIX
| Q4 25 | $431.1M | $450.0M | ||
| Q3 25 | $433.7M | $442.5M | ||
| Q2 25 | $438.2M | $458.3M | ||
| Q1 25 | $406.0M | $458.3M | ||
| Q4 24 | $398.0M | $503.1M | ||
| Q3 24 | $392.0M | $525.9M | ||
| Q2 24 | $365.8M | $546.0M | ||
| Q1 24 | $336.9M | $570.3M |
总资产EPACOFIX
| Q4 25 | $818.1M | $850.6M | ||
| Q3 25 | $827.9M | $832.6M | ||
| Q2 25 | $828.1M | $837.2M | ||
| Q1 25 | $776.6M | $823.1M | ||
| Q4 24 | $775.4M | $893.3M | ||
| Q3 24 | $777.3M | $867.9M | ||
| Q2 24 | $749.5M | $882.0M | ||
| Q1 24 | $769.3M | $906.0M |
负债/权益比EPACOFIX
| Q4 25 | 0.44× | — | ||
| Q3 25 | 0.44× | 0.36× | ||
| Q2 25 | 0.44× | 0.34× | ||
| Q1 25 | 0.47× | 0.34× | ||
| Q4 24 | 0.49× | 0.31× | ||
| Q3 24 | 0.50× | 0.23× | ||
| Q2 24 | 0.54× | 0.22× | ||
| Q1 24 | 0.73× | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $16.0M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $13.3M | $16.8M |
| 自由现金流率自由现金流/营收 | 9.2% | 7.6% |
| 资本支出强度资本支出/营收 | 1.9% | 4.9% |
| 现金转化率经营现金流/净利润 | 0.84× | — |
| 过去12个月自由现金流最近4个季度 | $102.5M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流EPACOFIX
| Q4 25 | $16.0M | $27.7M | ||
| Q3 25 | $55.3M | $12.4M | ||
| Q2 25 | $39.9M | $11.6M | ||
| Q1 25 | $7.5M | $-18.4M | ||
| Q4 24 | $8.6M | $23.7M | ||
| Q3 24 | $44.4M | $11.7M | ||
| Q2 24 | $30.3M | $9.0M | ||
| Q1 24 | $13.3M | $-18.6M |
自由现金流EPACOFIX
| Q4 25 | $13.3M | $16.8M | ||
| Q3 25 | $52.3M | $2.5M | ||
| Q2 25 | $35.1M | $4.5M | ||
| Q1 25 | $1.8M | $-25.1M | ||
| Q4 24 | $2.8M | $15.2M | ||
| Q3 24 | $37.9M | $6.3M | ||
| Q2 24 | $28.5M | $-360.0K | ||
| Q1 24 | $11.7M | $-29.1M |
自由现金流率EPACOFIX
| Q4 25 | 9.2% | 7.6% | ||
| Q3 25 | 31.2% | 1.2% | ||
| Q2 25 | 22.1% | 2.2% | ||
| Q1 25 | 1.2% | -13.0% | ||
| Q4 24 | 1.9% | 7.0% | ||
| Q3 24 | 23.9% | 3.2% | ||
| Q2 24 | 18.9% | -0.2% | ||
| Q1 24 | 8.5% | -15.4% |
资本支出强度EPACOFIX
| Q4 25 | 1.9% | 4.9% | ||
| Q3 25 | 1.8% | 4.8% | ||
| Q2 25 | 3.1% | 3.5% | ||
| Q1 25 | 3.9% | 3.5% | ||
| Q4 24 | 4.0% | 4.0% | ||
| Q3 24 | 4.1% | 2.7% | ||
| Q2 24 | 1.2% | 4.7% | ||
| Q1 24 | 1.1% | 5.6% |
现金转化率EPACOFIX
| Q4 25 | 0.84× | — | ||
| Q3 25 | 1.97× | — | ||
| Q2 25 | 1.81× | — | ||
| Q1 25 | 0.36× | — | ||
| Q4 24 | 0.40× | — | ||
| Q3 24 | 1.82× | — | ||
| Q2 24 | 1.18× | — | ||
| Q1 24 | 0.75× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EPAC
| Transferred At Point In Time | $126.0M | 87% |
| Other | $12.1M | 8% |
| Other Operating Segment | $6.1M | 4% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
